Qing Chang

1.7k total citations
20 papers, 335 citations indexed

About

Qing Chang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Qing Chang has authored 20 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Qing Chang's work include CAR-T cell therapy research (3 papers), Lung Cancer Research Studies (3 papers) and Neuroendocrine Tumor Research Advances (2 papers). Qing Chang is often cited by papers focused on CAR-T cell therapy research (3 papers), Lung Cancer Research Studies (3 papers) and Neuroendocrine Tumor Research Advances (2 papers). Qing Chang collaborates with scholars based in United States, China and Germany. Qing Chang's co-authors include Shaohui Zhang, Wenquan Wang, Jialing Wang, Xiaomin Wang, Qiuyun Guo, Ying Huang, Libo Zhao, Xiujuan Chen, Elisa de Stanchina and Helena A. Yu and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

Qing Chang

17 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qing Chang United States 8 135 126 71 48 43 20 335
Qiuyun Guo China 9 157 1.2× 56 0.4× 59 0.8× 29 0.6× 57 1.3× 13 309
Xiaohui Ye China 9 110 0.8× 35 0.3× 28 0.4× 70 1.5× 35 0.8× 24 324
Oana Baldasici Romania 6 206 1.5× 137 1.1× 55 0.8× 26 0.5× 100 2.3× 11 443
Xiaogang Sun China 10 180 1.3× 112 0.9× 46 0.6× 54 1.1× 95 2.2× 14 376
Jesse D. Gelles United States 9 203 1.5× 46 0.4× 46 0.6× 35 0.7× 46 1.1× 16 314
Xiaowei Meng China 10 159 1.2× 61 0.5× 100 1.4× 15 0.3× 84 2.0× 27 303
Junhong Hu China 10 139 1.0× 59 0.5× 45 0.6× 14 0.3× 72 1.7× 19 281
Huifeng Gao China 13 214 1.6× 117 0.9× 68 1.0× 23 0.5× 106 2.5× 23 402

Countries citing papers authored by Qing Chang

Since Specialization
Citations

This map shows the geographic impact of Qing Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qing Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qing Chang more than expected).

Fields of papers citing papers by Qing Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qing Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qing Chang. The network helps show where Qing Chang may publish in the future.

Co-authorship network of co-authors of Qing Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Qing Chang. A scholar is included among the top collaborators of Qing Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qing Chang. Qing Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mao, Ninghui, Young Sun Lee, Zeda Zhang, et al.. (2025). Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers. Science Advances. 11(6). eadq3802–eadq3802. 5 indexed citations
2.
Gadal, Sunyana, Jacob A. Boyer, Simon F. Roy, et al.. (2025). Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer Research. 85(9). 1611–1627.
3.
4.
Haubner, Sascha, Jorge Mansilla‐Soto, Sarah Nataraj, et al.. (2023). Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 41(11). 1871–1891.e6. 58 indexed citations
5.
Haubner, Sascha, Jorge Mansilla‐Soto, Sarah Nataraj, et al.. (2023). S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS. HemaSphere. 7(S3). e776231c–e776231c. 2 indexed citations
6.
Choi, Seo‐Hyun, Jin K. Kim, Chin‐Tung Chen, et al.. (2022). KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer. Molecular Cancer Research. 20(8). 1305–1319. 9 indexed citations
7.
Haubner, Sascha, Jorge Mansilla‐Soto, Sarah Nataraj, et al.. (2022). Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity. Blood. 140(Supplement 1). 869–870. 2 indexed citations
8.
Duan, Shanshan, Loredana Moro, Rui Qu, et al.. (2021). Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis. Cell Reports. 37(3). 109870–109870. 24 indexed citations
9.
Odintsov, Igor, Kota Ishizawa, Lukas Delasos, et al.. (2021). Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations. Molecular Cancer Therapeutics. 20(12_Supplement). P233–P233. 5 indexed citations
10.
Zhou, He, et al.. (2020). Effect of Early Treadmill Exercise and Massage on Activative Factors of Muscle Satellite Cells after Acute Injury of Skeletal Muscle in Rats. 26(1). 49–54.
11.
Russell, James, Milan Grkovski, Teja Kalidindi, et al.. (2020). Predicting Gemcitabine Delivery by18F-FAC PET in Murine Models of Pancreatic Cancer. Journal of Nuclear Medicine. 62(2). 195–200. 7 indexed citations
12.
Liu, Xiufang, et al.. (2019). Upregulation of CBP by PLY can cause permeability of blood‐brain barrier to increase meningitis. Journal of Biochemical and Molecular Toxicology. 33(7). e22333–e22333. 12 indexed citations
13.
Yu, Helena A., Leslie Perez, Qing Chang, et al.. (2016). A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology. 12(1). 102–109. 41 indexed citations
14.
Zhao, Libo, Xiaomin Wang, Qing Chang, et al.. (2009). Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. European Journal of Pharmacology. 627(1-3). 304–312. 119 indexed citations
15.
Chang, Qing, et al.. (2006). Transfection of antisense oligodeoxynucleotide inhibits heparanase gene expression and invasive ability of human pancreatic cancer cellin vitro. Journal of Huazhong University of Science and Technology [Medical Sciences]. 26(1). 72–74. 7 indexed citations
16.
Huang, Tao, et al.. (2006). Inhibition of metastatic progression of SSTR2 gene transfection mediated by adenovirus in human pancreatic carcinoma cells. Journal of Huazhong University of Science and Technology [Medical Sciences]. 26(1). 68–71. 8 indexed citations
17.
Chang, Qing. (2005). Histological study of the organogenesis of the digestive system of the tonguefish, Cynoglossus semilaevis. JOURNAL OF FISHERIES OF CHINA. 1 indexed citations
19.
Qin, Renyi, et al.. (2004). Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene. World Journal of Gastroenterology. 10(15). 2292–2292. 2 indexed citations
20.
Qin, Renyi, et al.. (2004). Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis. World Journal of Gastroenterology. 10(1). 132–132. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026